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Human trisomies can alter cellular phenotypes and
produce congenital abnormalities such as Down
syndrome (DS). Here we have generated induced
pluripotent stem cells (iPSCs) from DS fibroblasts
and introduced a TKNEO transgene into one copy
of chromosome 21 by gene targeting. When select-
ing against TKNEO, spontaneous chromosome loss
was the most common cause for survival, with a
frequency of 104, while point mutations, epige-
netic silencing, and TKNEO deletions occurred at
lower frequencies in this unbiased comparison of in-
activating mutations. Mitotic recombination events
resulting in extended loss of heterozygosity were
not observed in DS iPSCs. The derived, disomic
cells proliferated faster and produced more endo-
thelia in vivo than their otherwise isogenic trisomic
counterparts, but in vitro hematopoietic differ-
entiation was not consistently altered. Our study
describes a targeted removal of a human trisomy,
which could prove useful in both clinical and
research applications.Results and Discussion
Human trisomies are a major health problem, accounting for
23% of spontaneous abortions (Hassold et al., 1980). Down
syndrome (DS) is the most frequent autosomal trisomy (chro-
mosome 21), with numerous clinical manifestations including
heart defects, impaired cognition, premature aging, and
a high frequency of specific leukemias (Hasle et al., 2000).
Trisomies produce diverse effects on cultured cells. Fibroblasts
from trisomic mice proliferate slowly and have increased sensi-
tivity to specific drugs (Tang et al., 2011; Williams et al., 2008),
while human pluripotent stem cells with trisomy 12 or 17 have
an apparent growth advantage in vitro (Baker et al., 2007). In
DS, the effects of an extra copy of chromosome 21 have
been studied by comparing normal and trisomic cells from
distinct individuals (Chou et al., 2008; Costa et al., 2010;
Crossen and Morgan, 1980; Segal and McCoy, 1974; Sikora
et al., 1993), where differences in age, medical history, genetic
polymorphisms, and cell passaging may have influenced re-
sults. Ideally, the effects of human trisomy should be compared
in otherwise isogenic, disomic cell lines, as done previously inCellyeast (Torres et al., 2010) and mice (Tang et al., 2011; Williams
et al., 2008).
Induced pluripotent stem cells (iPSCs) offer a promisingway to
study human trisomy because they can be derived from the
somatic cells of trisomic individuals or fetuses, cultured indefi-
nitely, and differentiated into diverse cell types. We generated
six independent iPSC lines from DS fibroblasts as described
(Yu et al., 2007) and validated their trisomy 21 karyotypes
(example in Figure S1A available online). These iPSCs were
used to derive disomic subclones as outlined in Figure 1A. A
TKNEO fusion gene encoding both thymidine kinase and
neomycin resistance was introduced into chromosome 21 of
DS iPSCs for positive-negative selection. The Amyloid Precursor
Protein (APP) gene was chosen as the target locus due to its
location on the long arm of chromosome 21 and high expression
in iPSCs. The adeno-associated virus vector AAV-APPe3ITKNA
was used to introduce an internal ribosome entry site (IRES)-
TKNEO-polyadenylation site cassette into exon 3 of the APP
gene by homologous recombination (Figure 1A). Five trans-
duced, G418-resistant clones were isolated from each of three
DS iPSC lines and analyzed by Southern blots. Twelve of these
clones were targeted correctly at one APP allele and lacked
random integrants (Figure 1B). Based on these results, 0.14%
of all iPSC colony-forming units (CFUs) underwent gene target-
ing (Table S1 available online), comparable to previous reports
(Chamberlain et al., 2004; Khan et al., 2010).
APP-targeted clones were cultured in the absence of G418
selection for three passages to allow chromosome loss to take
place, and then were cultured in the presence of gancyclovir
(GCV) to select against TKNEO expression. A total of 33 GCV-
resistant clones derived from four different DS iPSCs were
screened for disomy by quantitative Southern blot analysis using
three probes from the long arm of chromosome 21 (centromeric,
APP target locus, and telomeric) and a reference probe on chro-
mosome 6 (Figure 1C). By comparison to trisomic and disomic
controls, we determined that 23 of the 33 GCV-resistant clones
had lost one copy of chromosome 21. Seven of these clones
were karyotyped (Table S2) and all had two copies of chromo-
some 21 (example in Figure S1A), validating the Southern blot
method and demonstrating that disomic iPSCs had been derived
from trisomic DS iPSCs. We also showed that different copies of
chromosome 21 had been targeted and lost, based on SNP
analysis of the disomic clones (Figure S1B).
Because the targeted copy of chromosome 21 was not
required for cell growth, we were able to measure the frequen-
cies of all causes of GCV resistance without bias. Overall, lossStem Cell 11, 615–619, November 2, 2012 ª2012 Elsevier Inc. 615
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Figure 1. Targeting and Removal of Chromosome 21 from DS iPSCs
(A) Schematic overview of experimental approach.
(B) Identification of chromosome 21 targeted clones. Maps of untargeted and targeted APP loci are shown. X, Xba I sites. The Southern blots show parental DS
iPSC clones C1, C2, and C3 and their derived G418-resistant subclones after digestion with Xba I and being probed for APP or TKNEO.
(C) Copy numbers of three chromosome 21 loci and a chromosome 6 control locus were determined by quantitative Southern blots in 33 GCV-resistant sub-
clones. Probe loci are shown in matched colors.
(D) TKNEO transgene presence in a subset of GCVR subclones as shown by Southern blot using a TKNEO probe. Parental trisomic iPSCs (C2) and targeted
trisomic iPSCs (C2-4) were included as controls.
(E) Northern blot demonstrating TKNEO gene expression in a subset of the GCVR subclones containing TKNEO transgenes. Parental trisomic iPSCs (C2) and
targeted trisomic iPSCs (C2-4) were included as controls.
(F) TKNEO coding region mutations found in the five GCVR subclones with expressed TKNEO transgenes. Wild-type sequences are shown above in red and
mutant sequences are shown below in blue.
(G) Total frequency of GCV resistance and the percentage of GCVR subclones due to each type of event.
See also Figure S1 and Tables S1 and S2.
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Trisomy Correction in Down Syndrome iPSCsof an entire copy of chromosome 21 was the most common
cause in five out of five independent experiments with an
average frequency of 1.4 3 104. The remaining 10 clones
were characterized further to determine the basis for their GCV
resistance. Southern blots showed that eight clones were still
trisomic at chromosome 21 (Figure 1C and Table S2). Six of
these contained the TKNEO gene, which was either mutated in616 Cell Stem Cell 11, 615–619, November 2, 2012 ª2012 Elsevier Inthe coding region (five clones) or silenced based on the lack of
mRNA expression (one clone) (Figures 1D–1F). The frequencies
of TKNEO coding mutations and silencing in DS iPSCs were
similar to those observed previously in mouse ESCs (Chan
et al., 2001). Two other trisomy 21 clones (C1-5-13 and C3-5-
10) had lost the TKNEO gene. These TKNEO deletions were
analyzed further to see if loss of heterozygosity (LOH) extendingc.
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Figure 2. Proliferation and Gene Expression of Trisomic and Disomic iPSCs
(A) Mixed culture measurements of trisomic and disomic iPSCs (initial seeding with 90% trisomic cells) by Southern blot analysis with TKNEO and chromosome 6
probes at 0, 3, and 7 passages. Representative blots with trisomic clone C2-4, disomic subclone C2-4-4, and pure cell population controls are shown. At right, the
trisomic cell percentages of four mixed cultures are shown (solid lines). Controls (dashed lines) included cultures with trisomic cells containing mutated TKNEO
transgenes (TKM C2-4-1 and C2-4-2).
(B) Growth curves of two isogenic pairs of iPSCs.
(C) The percents of G1, S, and G2/M phase cells as determined by BrdU-PI labeling in trisomic and disomic cells with representative flow cytometry examples
shown below. Bars are color-coded as indicated below for (C)–(E).
(D and E) The percentages of SSEA3+ pluripotent cells (D) and Annexin V+ apoptotic cells (E) as determined by flow cytometry of trisomic and disomic clones, with
examples shown at the right.
(F) Percentage of trisomic iPSCs present in mixed cultures performed in the absence of drugs or in the presence of 200 nM 17-AAG, 1 mM AICAR, 10 mM
chloroquine, 200 nM 17-AAG plus 1 mM AICAR, or 20 ng/ml cytarabine. DNA samples were obtained at the initial plating and after 15 days in culture.
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Trisomy Correction in Down Syndrome iPSCsfrom a recombination crossover point to the telomere had
occurred. However, three distinct chromosome 21 haplotypes
were present based on SNP analysis, suggesting that more
localized gene conversion events were responsible (Figure S1C).
The absence of clones with extended LOH was unexpected
because this is a major cause of gene inactivation/loss in mouse
ESCs and human lymphocytes (Chan et al., 2001; Gupta et al.,
1997; Lefebvre et al., 2001). The two remaining GCV-resistant
clones contained three copies of a portion of chromosome 21
(Figure 1C), but only two copies of more telomeric sequences.
One of these clones contained a silenced TKNEO gene (C1-5-
12), while the other lacked TKNEO and was disomic at chromo-
some 21 by karyotyping (C3-1-2), suggesting that there may
have been a localized duplication of pericentromeric sequences
not detected by cytogenetic analysis. Based on this classifica-
tion, the different causes of GCV resistance were chromosome
loss > TKNEO coding mutation > TKNEO transgene deletion >
TKNEO transgene silencing (Figure 1G).
DS fibroblasts and lymphocytes have been reported to have
either increased or decreased cell growth in comparison to non-
isogenic, disomic cells (Crossen and Morgan, 1980; Segal and
McCoy, 1974; Sikora et al., 1993). Wemeasured the proliferation
of four passage-matched, isogenic pairs of disomic and trisomic
iPSCs and two control pairs with GCV-resistant trisomic clones
that had TKNEO mutations, using mixed cultures in which we
tracked the percentage of trisomic cells by Southern blots for
the TKNEO gene (Figure 2A). In all cases the disomic cells
expanded preferentially during coculture, with an average popu-
lation doubling time of 37 ± 0.7 hr as compared to 45 ± 0.9 hr for
trisomic cells. Pure cultures of disomic clones also expanded
more quickly than their trisomic counterparts, with 3–7 hr shorter
doubling times during the proliferative period (Figure 2B). Our
results are consistent with those obtained from isogenic mouse
cell lines showing that trisomies inhibit proliferation (Williams
et al., 2008) and with the observation that disomy 21 mosaicism
increases over time in DS (Jenkins et al., 1997). Based on the
profiling of cell cycle phases with bromodeoxyuridine (BrdU)
and propidium iodide (PI), a greater percentage of trisomic cells
were in the G1 phase (Figure 2C), which was not found in mouse
trisomymodels (Williams et al., 2008). These results were not due
to altered differentiation kinetics or apoptosis, since expression
of the pluripotency surface marker SSEA3 and the apoptosis
marker Annexin V were similar in disomic and trisomic cells
(Figures 2D and 2E).
The impaired proliferation of trisomic cells has been attributed
to gene dosage effects and compensatory changes in protein
degradation and energy consumption that result in increased
sensitivity to compounds affecting these processes (Tang et al.,
2011). We performed mixed culture proliferation experiments in
the presence of three of these compounds (17-allylamino-17-
demethoxygeldanamycin [17-AAG], 5-aminoimidazole-4-car-
boxamide riboside [AICAR], and chloroquine), but even at the
highest tolerated doses, none of these drugs selectively inhibited
the proliferation of trisomy 21 iPSCs (Figure 2F). Thus, the(G) Average gene expression changes for each chromosome in trisomic iPSC
listed.
p values in (C)–(E) and (G) were determined by paired t tests. Data in (B and G) a
See also Figure S2.
618 Cell Stem Cell 11, 615–619, November 2, 2012 ª2012 Elsevier Inimpaired proliferation of trisomic DS iPSCs is not due to the
same alterations in protein degradation and energy consumption
observed in trisomic mouse fibroblasts (Tang et al., 2011). We
also measured proliferation in the presence of cytarabine (Fig-
ure 2F) because DS leukemia cells are particularly sensitive to
this drug (Zwaan et al., 2002); however, no differences were
observed.
We compared the global gene expression profiles of two
parental trisomic iPSCs, four derived disomic iPSCs, and human
embryonic stem cells (H1 ESCs). Pearson correlation analysis
showed that both trisomic and disomic iPSCs clustered closely
together (coefficients >0.98), similar to replicate samples of H1
ESCs. A direct comparison of isogenic trisomic and disomic
pairs showed the expected upregulation of chromosome 21
genes with trisomy, and remarkably little additional variation.
Only three other genes were >2-fold dysregulated in trisomic
cells: ACTA2, PTRF, and RPL39L were overexpressed (Fig-
ure 2G). It is tempting to speculate that altered expression of
ACTA2 (Alpha 2 actin) may play a role in DS cardiovascular
malformations because ACTA2 mutations are known to cause
vascular abnormalities (Guo et al., 2007).
Trisomy 21 has been proposed to influence hematopoietic and
endothelial differentiation (Baek et al., 2009; Chou et al., 2008;
Reynolds et al., 2010). We analyzed cells from day 14 embryoid
bodies (EBs) for the presence of hematopoietic and endothelial
surface markers and progenitor cells, but did not detect consis-
tent differences between two isogenic pairs of trisomic and
disomic iPSCs (Figures S2A–S2C), arguing that this in vitro
model poorly recapitulates the known effects of trisomy 21 on
hematopoiesis during human development (Fong and Brodeur,
1987). In vivo, all four clones formed trilineage teratomas after
implantation into immunodeficient mice (example in Figure S2D),
and the trisomic lines produced fewer endothelia within these
teratomas (Figure S2E). Impaired endothelia formation is con-
sistent with prior observations of DS cells (Baek et al., 2009;
Reynolds et al., 2010), suggesting that in vivo modeling may be
more accurate.
In summary, we have generated DS iPSCs and removed the
extra copy of chromosome 21 by a combination of gene target-
ing and negative selection. Our study provides ameasurement of
spontaneous mutation frequencies in human pluripotent stem
cells, with chromosome loss being the most common cause of
GCV resistance. Previously, an alternative strategy for chromo-
some loss was described in mouse cells that consisted of
Cre-mediated recombination at engineered, inverted loxP sites
(Lewandoski andMartin, 1997). The advantages of our approach
are that recombinase protein is not required, abnormal chromo-
somal forms are not produced, and the frequency of sponta-
neous chromosome loss can be measured.
Trisomy removal has practical applications. DS patients have
a 10- to 20-fold increased risk of leukemia (Fong and Brodeur,
1987), so trisomy removal might eventually be used to treat DS
leukemia by autologous transplantation of patient-derived, diso-
mic cells that lack the proleukemic effects of the extra copy ofs. Genes with >2-fold induction and statistical significance (p < 0.05) are
re represented as mean ± SEM.
c.
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Trisomy Correction in Down Syndrome iPSCschromosome 21. Our approach could also be used to eliminate
the unwanted trisomies that frequently arise during stem cell
culture (Draper et al., 2004; Mayshar et al., 2010), thereby allow-
ing one to revert a valuable, trisomic clone to a normal karyotype.
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